DACT2
Dapper homolog 2
Protein Summary
Involved in regulation of intracellular signaling pathways during development. Negatively regulates the Nodal signaling pathway, possibly by promoting the lysosomal degradation of Nodal receptors, such as TGFBR1. May be involved in control of the morphogenetic behavior of kidney ureteric bud cells by keeping cells epithelial and restraining their mesenchymal character. May play an inhibitory role in the re-epithelialization of skin wounds by attenuating TGF-beta signaling (By similarity).
- ENST00000366795
- ENSP00000355760
- ENSG00000164488
- ENST00000366796
- ENSP00000355761
- ENST00000607983
- ENSP00000476434
- ENST00000610183
- ENSP00000476573
- C6orf116
- DPR2
- DAPPER2
- C6orf116
- bA503C24.7
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
tissue sample | 0.73 | ||
tissue | 0.54 | ||
PubMedID | 0.48 | ||
gene perturbation | 0.44 | ||
cell line | 0.43 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 32.02 (req: < 5)
Gene RIFs: 23 (req: <= 3)
Antibodies: 61 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 32.02 (req: >= 5)
Gene RIFs: 23 (req: > 3)
Antibodies: 61 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 11
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0